| Literature DB >> 32677095 |
Katharine L Lewis1,2,3, Collin K Chin4, Kate Manos5, John Casey6, Nada Hamad7, Julie Crawford1,8, Shir-Jing Ho9, Samar Issa10, Andrew Grigg5, Peter Wood11, Maher K Gandhi11, Bryan Do4, Loretta Nastoupil4, Eliza A Hawkes5,12,13, Chan Y Cheah1,2,3,8.
Abstract
Primary and secondary central nervous system lymphomas (PCNSL/SCNSL) are aggressive rare malignancies with dismal outcomes. Encouraging data have emerged from Phase I/II clinical trials treating relapsed/refractory PCNSL/SCNSL with ibrutinib. We analysed 33 patients who received ibrutinib, alone or with other therapies, for PCNSL (n = 9) or SCNSL (n = 24). The objective response rate was 58% (complete response 55%). The median progression-free survival and overall survival for patients with PCNSL were both 3·1 months; for SCNSL, 10·2 and 11·5 months respectively. Only one invasive fungal infection was observed, despite concurrent or recent use of dexamethasone 8-16 mg daily in 14 patients (42%). Ibrutinib has encouraging activity in these aggressive malignancies.Entities:
Keywords: BTK inhibitor; central nervous system; ibrutinib; lymphoma; novel
Mesh：
Substances：
Year: 2020 PMID： 32677095 DOI： 10.1111/bjh.16946
Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 6.998